Skip to main content

Advertisement

SpringerLink
Log in

Combination drug therapy for combined hyperlipidemia

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Combination therapy for hyperlipidemia, especially combined hyperlipidemia, may have advantages over single drug therapy, affording better improvement in lipoprotein risk factors and possibly better prevention of atherothrombotic events. Although preliminary experience has been gained using treatment combinations of niacin with statins, and fibrates with statins, few studies have focused on angiographic or clinical outcomes. Both of these treatment combinations increase the risk of drug-induced myopathy and rhabdomyolysis. Current estimates of myopathy incidence are much lower than original estimates, but the relative safety of combined therapy might depend upon employing low or moderate statin doses. Safety depends critically upon educating the patient to respond appropriately to muscle symptoms, to intercurrent illness, and to concurrent use of certain other medications. Other useful drug combinations include those derived by addition of fish oil, bile acid binding resins, or stanol esters, as well as nonstatin combinations such as niacin-resin or fibrate-niacin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and recommended reading

  1. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994, 344:1383–1389.

    Article  Google Scholar 

  2. Frick MH, Elo O, Haapa K, et al.: Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987, 317:1237–1245.

    Article  PubMed  CAS  Google Scholar 

  3. The Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. J Am Med Assoc. 1975, 231:360–381.

    Article  Google Scholar 

  4. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. J Am Med Assoc. 1984, 251:351–374.

    Article  Google Scholar 

  5. Carlson LA, Oro L: Effect of treatment with nicotinic acid for one month on serum lipids in patients with different types of hyperlipidemia. Atherosclerosis. 1973, 18:1–9.

    Article  PubMed  CAS  Google Scholar 

  6. Morgan JM, Capuzzi DM, Guyton JR, et al.: Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Therapeut. 1996, 1:195–202.

    CAS  Google Scholar 

  7. Knopp RH, Alagona P, Davidson M, et al.: Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism. 1998, 47:1097–1104.

    Article  PubMed  CAS  Google Scholar 

  8. Knopp RH, Ginsberg J, Albers JJ, et al.: Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism. 1985, 34:642–650.

    Article  PubMed  CAS  Google Scholar 

  9. Davignon J, Roederer G, Montigny M, et al.: Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol. 1994, 73:339–345.

    Article  PubMed  CAS  Google Scholar 

  10. McKenney JM, Proctor JD, Harris S, Chinchili VM: A comparison of the efficacy and toxic effects of sustained-vs immediate-release niacin in hypercholesterolemic patients. J Am Med Assoc. 1994, 271:672–677.

    Article  CAS  Google Scholar 

  11. • Guyton JR, Goldberg AC, Kreisberg RA, et al.: Effectiveness of once nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol. 1998, 82:737–743.

    Article  PubMed  CAS  Google Scholar 

A new, better-tolerated niacin formulation (Niaspan) was used in combination with statins in 53 patients, giving enhanced LDL lowering and HDL raising. Although Niaspan is an extended-release niacin, hepatic safety appears well documented

  1. • Guyton JR, Capuzzi DM: Treatment of hyperlipidemia with combined niacin-statin regimens. Am J Cardiol. 1998, 82:82U-84U.

    Article  PubMed  CAS  Google Scholar 

A more complete compilation of niacin-statin studies is given, as well as extension of the Niaspan-statin data to 165 patients

  1. Capuzzi DM, Guyton JR, Morgan JM, et al.: Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol. 1998, 82:74U-81U.

    Article  PubMed  CAS  Google Scholar 

  2. Merck & Company: Product information for Mevacor (lovastatin). In Physician’s Desk Reference. Montvale, New Jersey: Medical Economics Company; 1996:1701.

    Google Scholar 

  3. Reaven P, Witztum JL: Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med. 1988, 109:597–598.

    PubMed  CAS  Google Scholar 

  4. Cooke HM: Lovastatin- and niacin-induced rhabdomyolysis. Hospital Pharmacy. 1994, 29:33–34.

    Google Scholar 

  5. Committee of Principal Investigators: A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J. 1978, 40:1069–1118.

    Google Scholar 

  6. Parke-Davis: Product information for Lopid (gemfibrozil). In Physician’s Desk Reference. Montvale, New Jersey: Medical Economics Company; 1999.

    Google Scholar 

  7. Rubins HB, Robins SJ, Collins D: The Veterans Affairs High-Density Lipoprotein Intervention Trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Veterans Affairs Cooperative Studies Program High-Density Lipoprotein Intervention Trial Study Group. Am J Cardiol. 1996, 78:572–575.

    Article  PubMed  CAS  Google Scholar 

  8. Glueck CJ, Oakes N, Speirs J, et al.: Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias. Am J Cardiol 1992, 70:1–9.

    Article  PubMed  CAS  Google Scholar 

  9. Pierce LR, Wysowski DK, Gross TP: Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. J Am Med Assoc. 1990, 264:71–75.

    Article  CAS  Google Scholar 

  10. Smith AF, Macfie WG, Oliver MF: Clofibrate, serum enzymes, and muscle pain. Br Med J. 1970, 2:86–88.

    PubMed  Google Scholar 

  11. Magarian GJ, Lucas LM, Colley C: Gemfibrozil-induced myopathy. Arch Intern Med. 1991, 151:1873–1874.

    Article  PubMed  CAS  Google Scholar 

  12. Harris WS: Dietary fish oil and blood lipids. Curr Opin Lipidol 1996, 7:3–7.

    Article  PubMed  CAS  Google Scholar 

  13. Sprecher DL, Abrams J, Allen JW, et al.: Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med. 1994, 120:537–543.

    PubMed  CAS  Google Scholar 

  14. East C, Bilheimer DW, Grundy SM. Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med. 1988, 109:25–32.

    PubMed  CAS  Google Scholar 

  15. Gordon DJ, Knoke J, Probstfield JL, et al.: High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. Circulation. 1986, 74:1217–1225.

    PubMed  CAS  Google Scholar 

  16. Brown BG, Albers JJ, Fisher LD, et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990, 323:1289–1298.

    Article  PubMed  CAS  Google Scholar 

  17. Miettinen TA, Puska P, Gylling H, et al.: Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med. 1995, 333:1308–1312.

    Article  PubMed  CAS  Google Scholar 

  18. Pasternak RC, Brown LE, Stone PH, et al.: Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and “normal” cholesterol levels. A randomized, placebo-controlled trial. Ann Intern Med. 1996, 125:529–540.

    PubMed  CAS  Google Scholar 

  19. Sacks FM, Pasternak RC, Gibson CM, et al.: Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolemic patients. Lancet. 1994, 344:1182–1186.

    Article  PubMed  CAS  Google Scholar 

  20. Carlson LA, Rosenhamer G: Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988, 223:405–418.

    Article  PubMed  CAS  Google Scholar 

  21. Kane JP, Malloy MJ, Ports TA, et al.: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. J Am Med Assoc. 1990, 264:3007–3012.

    Article  CAS  Google Scholar 

  22. Blankenhorn DH, Nessim SA, Johnson RL, et al.: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. J Am Med Assoc. 1987, 257:3233–3240.

    Article  CAS  Google Scholar 

  23. Brown BG, Bardsley J, Poulin D, et al.: Moderate dose, threedrug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol < 100 mg/dl in patients with hyperlipidemia and coronary artery disease. Am J Cardiol 1997, 80:111–115.

    Article  PubMed  CAS  Google Scholar 

  24. Jacobson TA, Chin MM, Fromell GJ, et al.: Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol. 1994, 74:149–154.

    Article  PubMed  CAS  Google Scholar 

  25. O’Keefe JH, Jr., Harris WS, Nelson J, Windsor SL: Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am J Cardiol. 1995, 76:480–484.

    Article  PubMed  CAS  Google Scholar 

  26. Gardner SF, Schneider EF, Granberry MC, Carter IR: Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin. Pharmacotherapy. 1996, 16:419–423.

    PubMed  CAS  Google Scholar 

  27. Gardner SF, Marx MA, White LM, et al.: Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control. Ann Pharmacother. 1997, 31:677–682.

    PubMed  CAS  Google Scholar 

  28. Vacek JL, Dittmeier G, Chiarelli T, et al.: Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia. Am J Cardiol. 1995, 76:182–184.

    Article  PubMed  CAS  Google Scholar 

  29. Wiklund O, Angelin B, Bergman M, et al.: Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med. 1993, 94:13–20.

    Article  PubMed  CAS  Google Scholar 

  30. Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al.: Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol. 1997, 80:608–613.

    Article  PubMed  CAS  Google Scholar 

  31. Ellen RL, McPherson R: Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol. 1998, 81:60B-65B.

    Article  PubMed  CAS  Google Scholar 

  32. Iliadis EA, Rosenson RS: Long-term safety of pravastatingemfibrozil therapy in mixed hyperlipidemia. Clin Cardiol 1999, 22:25–28.

    Article  PubMed  CAS  Google Scholar 

  33. Zambon D, Ros E, Rodriguez-Villar C, et al.: Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation. Metabolism. 1999, 48:47–54.

    Article  PubMed  CAS  Google Scholar 

  34. • Kayikcioglu M, Ozerkan F, Soydan I: Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia. Am J Cardiol. 1999, 83:1135–1137.

    Article  PubMed  CAS  Google Scholar 

The data suggest that giving simvastatin and fenofibrate on alternate days may be just as effective in correcting dyslipidemia as giving twice the treatment doses (the same doses of both drugs every day)

  1. Contacos C, Barter PJ, Sullivan DR: Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia. Arterioscler Thromb 1993, 13:1755–1762.

    PubMed  CAS  Google Scholar 

  2. Davidson MH, Macariola-Coad JR, McDonald AM, et al.: Separate and joint effects of marine oil and simvastatin in patients with combined hyperlipidemia. Am J Cardiol. 1997, 80:797–798.

    Article  PubMed  CAS  Google Scholar 

  3. Spencer GA, Wirebaugh S, Whitney EJ: Effect of a combination of gemfibrozil and niacin on lipid levels. J Clin Pharmacol 1996, 36:696–700.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Duke University Medical Center, Box 3510, 27710, Durham, NC, USA

    John R. Guyton MD

Authors
  1. John R. Guyton MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guyton, J.R. Combination drug therapy for combined hyperlipidemia. Curr Cardiol Rep 1, 244–250 (1999). https://doi.org/10.1007/s11886-999-0030-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-999-0030-z

Keywords

Search

Navigation